Author(s): MacConaill LE
Abstract Share this page
Abstract Although improvements in genomic technologies during the past decade have greatly advanced our understanding of the genomic alterations that contribute to lung cancer, and the disease has (to a degree) become a paradigm for individualized cancer treatment in solid tumors, additional challenges must be addressed before the goal of personalized cancer therapy can become a reality for lung cancer patients.
This article was published in Arch Pathol Lab Med
and referenced in Journal of Integrative Oncology